Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

81. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P CRD summary The authors concluded that probiotics may alleviate some symptoms of irritable bowel syndrome after several weeks of treatment. Longer (...) -term studies were needed, focused on the type and optimal dose of probiotics and on subgroups of patients who may benefit. The review was well conducted and the conclusions appear reliable. Authors' objectives To determine whether probiotics alleviate the symptoms of irritable bowel syndrome. Searching MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, AMED and Cochrane Central Register of Controlled Trials were searched. A high-sensitivity filter was used in the EMBASE search

DARE.2009

82. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Rahimi R, Nikfar S, Rezaie A, Abdollahi M CRD summary This review concluded that low-dose tricyclic antidepressants (TCAs) exhibited clinically and statistically significant control of irritable bowel syndrome (IBS) symptoms. Caution is warranted (...) in the application of the results as reported TCA effects may have been overestimated given the small number of studies and patients reviewed. Authors' objectives To assess the efficacy of tricyclic antidepressants (TCAs) in patients with irritable bowel syndrome (IBS). Searching PubMed, Scopus, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) were searched (from 1966 to September 2008) for English-language papers. Search terms were reported. Reference lists of retrieved articles were

DARE.2009

83. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS CRD summary This review evaluated efficacy, safety and tolerability of probiotics in irritable bowel syndrome and concluded that Bifidobacterium infantis 35624 showed efficacy (...) in improving symptoms; data for other probiotics were inadequate. The conclusion that evidence on probiotics was of poor quality appeared appropriate, although conclusions about the efficacy of B. infantis may be less reliable. Authors' objectives To evaluate efficacy, safety and tolerability of probiotics in treatment of irritable bowel syndrome (IBS). Searching MEDLINE, PubMed, EMBASE and The Cochrane Library were searched from inception to June 2008 to identify relevant articles published in English

DARE.2009

84. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Ford A C, Chey W D, Talley N J, Malhotra A, Spiegel B M, Moayyedi, P CRD summary This generally well-conducted review concluded that the prevalence of biopsy (...) -proved celiac disease in individuals meeting the IBS diagnostic criteria is approximately 4% and the odds for biopsy-proved celiac disease is more than four-fold that in healthy controls. Interpretation of the results should be undertaken with some caution due to the limitations of the included studies and the between study heterogeneity. Authors' objectives To estimate the prevalence of celiac disease in adults who met the diagnostic criteria for irritable bowel syndrome (IBS). Searching MEDLINE

DARE.2009

85. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P CRD summary The authors concluded that antidepressants were effective (...) in the treatment of irritable bowel syndrome, and psychological therapies may be of comparable efficacy to antidepressants, but there was lack of high quality evidence. Given the risk of publication bias, the presence of statistical heterogeneity, and the low quality of available trials, the reliability of the authors' conclusions regarding antidepressants is unclear. Authors' objectives To assess the efficacy of anti-depressant medication and psychological therapies in alleviating symptoms of irritable bowel syndrome

DARE.2009

86. Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome

Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Article Text Diagnosis Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2009

87. Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome

Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Article Text Therapeutics Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Statistics from Altmetric.com No Altmetric data available for this article. QUESTION In patients

Evidence-Based Medicine (Requires free registration)2009

88. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial.

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. 19713235 2009 08 28 2009 09 10 2016 12 15 1756-1833 339 2009 Aug 27 BMJ (Clinical research ed.) BMJ Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. b3154 10.1136/bmj.b3154 bmj.b3154 To determine the effectiveness of increasing the dietary content of soluble fibre (psyllium) or insoluble fibre (bran) in patients with irritable bowel syndrome (...) . Randomised controlled trial. General practice. 275 patients aged 18-65 years with irritable bowel syndrome. 12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93). The primary end point was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritable bowel syndrome symptom severity score, severity

BMJ2009 Full Text: Link to full Text with Trip Pro

89. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome 18671775 2008 10 07 2009 02 20 2008 10 07 1365-2036 28 8 2008 Oct 15 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. 994-1002 10.1111/j.1365-2036.2008.03818.x The intestinal permeability (...) is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS. Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria

EvidenceUpdates2008

90. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? CONTEXT: Many individuals experience lower gastrointestinal tract symptoms, most commonly attributable to functional conditions. These individuals are frequently diagnosed with irritable bowel syndrome (IBS) based on their symptoms; however, some may require additional testing or referral to specialists before this diagnosis is made. OBJECTIVE (...) : To systematically review the literature of the accuracy of individual symptoms and combinations of findings in diagnosing IBS. DATA SOURCES: Search of MEDLINE and EMBASE (up to June 2008) for prospective studies reporting on unselected cohorts of adult patients with lower gastrointestinal tract symptoms recorded before investigation. STUDY SELECTION: Studies prospectively evaluating accuracy of individual symptoms or combinations of findings compared with results from investigations of the lower

JAMA2008

91. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome 18466359 2008 07 09 2008 10 13 2012 11 15 1365-2036 28 2 2008 Jul Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. 239-49 10.1111/j.1365-2036.2008.03730.x In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function. To evaluate the effects (...) of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial. Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure was number of months of adequate relief of IBS pain or discomfort, with a prospective plan to evaluate adequate relief data by entry baseline pain and subtype. Several other endpoints were also evaluated. Five hundred and ninety-six patients were

EvidenceUpdates2008

92. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents 18410774 2008 04 15 2008 05 06 2013 11 21 1097-6833 152 5 2008 May The Journal of pediatrics J. Pediatr. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. 685-9 10.1016/j.jpeds.2007.10.012 To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents. Adolescents 12 (...) to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed surveys at 2, 6, 10, and 13 weeks. Thirty-three patients (24 female) were enrolled. Patients receiving AMI were more likely to experience improvement from baseline in overall QOL at 6, 10, and 13 weeks (P = .019, .004, and .013). Patients

EvidenceUpdates2008

93. Effectiveness of probiotics in the treatment of irritable bowel syndrome

Effectiveness of probiotics in the treatment of irritable bowel syndrome 18363533 2008 03 26 2008 06 17 2008 03 26 0277-0008 28 4 2008 Apr Pharmacotherapy Pharmacotherapy Effectiveness of probiotics in the treatment of irritable bowel syndrome. 496-505 10.1592/phco.28.4.496 Recently, the use of tegaserod and alosetron -- drugs approved for the treatment of irritable bowel syndrome (IBS) -- has been restricted because of adverse events. This has resulted in a need for additional modalities (...) for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit time, and bacterial counts. Using the MEDLINE database from 1966-October 2007 and manually searching article references for relevant articles and abstracts, we identified 14 blinded, placebo-controlled clinical trials of the effectiveness of probiotics in the treatment of IBS. Of 11 studies in which overall

EvidenceUpdates2008

94. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review

Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review 18177446 2008 03 17 2008 06 06 2016 10 19 0002-9270 103 3 2008 Mar The American journal of gastroenterology Am. J. Gastroenterol. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. 765-74; quiz 775 10.1111/j.1572-0241.2007.01722.x Irritable bowel syndrome (IBS) is a common disorder that occurs in adults. The natural history of symptoms and risk (...) factors that contribute to IBS may begin in childhood. The aim of this systematic review was to determine what early life factors contribute to the development of IBS in adolescents and adults. A computer-assisted search of the PubMed database from 1966 to 2007 was performed. The selection criteria were: (a) studies conducted in adolescents or adults with IBS that (b) investigate premorbid factors occurring specifically during the childhood period and are (c) associated with the outcomes of symptoms

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

95. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.

Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. BACKGROUND: Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Although most children are managed by reassurance and simple measures, a large range of psychosocial (...) interventions including cognitive and behavioural treatments and family therapy have been recommended. OBJECTIVES: To determine the effectiveness of psychosocial interventions for recurrent abdominal pain or IBS in school-age children. SEARCH STRATEGY: The Cochrane Library (CENTRAL) 2006 (Issue 4), MEDLINE (1966 to Dec 2006), EMBASE (1980 to Dec 2006), CINAHL (1982 to Dec 2006), ERIC (1966 to Dec 2006), PsycINFO (1872 to Dec 2006), LILACS (1982 to Dec 2006), SIGLE (1980 to March 2005), and JICST (1985 to 06

Cochrane2008

96. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.

Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. BACKGROUND: Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority no organic cause for their pain can be found on physical examination or investigation and although most children are likely managed by reassurance and simple measures, a large range of interventions have been (...) with "abdominal migraine". Data before cross-over was not available. Results for 14 children showed Mean fewer days in pain of 8.21 (95% CI 2.93, 13.48) while taking the active drug. Kline et al compared peppermint oil capsules with placebo in a randomised trial in 50 children with RAP and IBS. 42 children completed the study. OR for improvement was 3.33 (95% CI 0.93-12.1)See et al compared famotidine with placebo in a randomised cross-over trial in 25 children with RAP and dyspepsia. OR for improvement

Cochrane2008

97. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome

The relationship between somatisation and outcome in patients with severe irritable bowel syndrome The relationship between somatisation and outcome in patients with severe irritable bowel syndrome The relationship between somatisation and outcome in patients with severe irritable bowel syndrome Creed F, Tomenson B, Guthrie E, Ratcliffe J, Fernandes L, Read N, Palmer S, Thompson D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of three treatments for patients with severe irritable bowel syndrome, which were brief interpersonal psychotherapy, paroxetine, and usual treatment. These were assessed for four quartiles of somatisation score. Both psychotherapy

NHS Economic Evaluation Database.2008

98. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome

Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome McCrone P, Knapp M, Kennedy T, Seed P, Jones R, Darnley S, Chalder T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to evaluate the cost-effectiveness of cognitive behavioural therapy (CBT) in addition to mebeverine for irritable bowel syndrome (IBS), compared with mebeverine only. The authors concluded that CBT plus mebeverine was cost-effective for patients with IBS in the short-term

NHS Economic Evaluation Database.2008

99. Clinical practice guideline: Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care

Clinical practice guideline: Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care

Royal College of Nursing2008

100. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M CRD summary This review evaluated whether probiotics could improve clinical symptoms of patients with irritable bowel syndrome. The authors (...) concluded that probiotics may improve irritable bowel syndrome symptoms compared to placebo. The review appeared well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To assess whether probiotics can improve the symptoms of patients with irritable bowel syndrome. Searching PubMed, EMBASE, Scopus, Web of Science and Cochrane Central Register of Controlled Trials were searched from 1996 to September 2007. Search terms were reported. Additional studies were searched

DARE.2008